Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2009-07-27
2011-12-20
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S359000
Reexamination Certificate
active
08080550
ABSTRACT:
The invention generally relates to anesthetic compositions comprising low doses of a selective a-2 adrenergic receptor agonists in combination with anesthetic agents. The invention also relates to methods of using these compositions; in particular, the use of these compositions in humans to enhance the efficacy of a local peripheral anesthetic injection. The compositions and the methods are particularly useful in regional block anesthetic injections, and more particularly, in dental anesthetic injections.
REFERENCES:
patent: 4663340 (1987-05-01), Najer et al.
patent: 5021416 (1991-06-01), Gluchowski
patent: 5300504 (1994-04-01), Gluchowski
patent: 5424078 (1995-06-01), Dziabo et al.
patent: 5561132 (1996-10-01), Burke et al.
patent: 5677321 (1997-10-01), Jeon et al.
patent: 5756503 (1998-05-01), Burke et al.
patent: 5804587 (1998-09-01), Cupps et al.
patent: 5914342 (1999-06-01), Maurer et al.
patent: 5916900 (1999-06-01), Cupps et al.
patent: 5948804 (1999-09-01), Jeon et al.
patent: 5965595 (1999-10-01), Maurer et al.
patent: 6040451 (2000-03-01), Jeon et al.
patent: 6087361 (2000-07-01), Munk et al.
patent: 6110952 (2000-08-01), Henry et al.
patent: 6117871 (2000-09-01), Maurer et al.
patent: 6159998 (2000-12-01), Jeon et al.
patent: 6162818 (2000-12-01), Henry et al.
patent: 6242442 (2001-06-01), Dean et al.
patent: 6534048 (2003-03-01), Borgman
patent: 6562873 (2003-05-01), Olejnik et al.
patent: 6627210 (2003-09-01), Olejnik et al.
patent: 6641834 (2003-11-01), Olejnik et al.
patent: 6673337 (2004-01-01), Olejnik et al.
patent: 6730065 (2004-05-01), Horn
patent: 6982079 (2006-01-01), Huth
patent: 2005/0020600 (2005-01-01), Scherer
Medical Management of Chronic Rhinosinusitus— Jean P. Fong, MD, Matthew Ryan, MD (May 2006).
Preven Drugs from Going Missing in Action—Mark B. Abelson, MD, and Sarah A. Rosner MPH; Review of Ophthalmology; www.revophth.com/index.asp?page=1—357.htm.
Interactions Between CA2+ and H+ and Functional Consequences in Vascular Smooth Muscle—C. Austin and S. Wray, Journ. of Amer. Heart Association (Circ Res. 2000;86:355-363).
A Useful New Topical Treatment For Glaucoma And Ocular Hypertension—Drug Ther Perspect 13(1):1-4, 1999.
Brimonidine In The Treatment of Glaucoma and Ocular Hypertension—Louis B. Cantor, Therapeutics And Clinical Risk Management 2006:2(4) 337-346.
Silent Bedpartners—Nancy A. Collop, Chest 2002; 122; 1111-1112.
Traitement Des Glaucomes Par La Brimonidine (Alphagan® 0,2 %)—M. Detry-Morel, C. Dutrieux, J Fr. Ophtalmol., 2000; 23, 8, 763-768.
Vasopressin-Induced Vasoconstriction: Two Concentration-Dependent Signaling Pathways—Kyle K. Henderson and Kenneth L. Bryon, J Appl Physiol 102: 1402-1409, 2007.
The Effect Of Correction Of Sleep-Disordered Breathing On Bp In Untreated Hypertension—K. MAE HLA, J. B. Skatrud, L. Finn, M. Palta and T. Young, Chest 2002;122; 1125-1135.
Myogenic Tone And Reactivity Of The Rat Ophthalmic Artery—Y. P. R. Jarajapu, M. B. Grant, and H. J. Knot, Invest. Ophth. & Visual Science, Jan. 2004, vol. 45, No. 1.
Correspondence A Propos De L'article: <<Traitement Des Claucomes Par La Brimonidine>>, M. Detry-Morel ET C. Dutrieux, J Fr Ophtalmol. 2000; 23(8): 763-8.
Prospective Study Of The Association Between Sleep-Disordered Breathing and Hypertension—P. Peppard, et. al., The New England J of Med., vol. 342, No. 19:1378-1384 (2000).
Catecholamines And Sympathomimetic Drugs—Goodman & Gilman's Pharmacology, Ch. 10; www.accessmedicine.com/popup.aspx?aID-936314&pring=yes—chapter.
Rhinitis Medicamentosa—JT Ramey, E Bailen, RF Lockey, J Investig Allergol Clin Immunol 2006; vol. 16(3); 148-155.
Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo—D.D. Rees, et al., br. J. Pharmacol. (1990) 101, 746-752.
Inhibition of α-adrenergic vasoconstriction in exercising human thigh muscles—D. Walter Wray, et al., J Physiol 555, 2 pp. 545-264 (2003).
Dexmedetomidine Enhances the Local Anesthetic Action of Lidocaine via . . . Tatsushi Yoshitomi DDS et al., Anesth Analg 2008; 107:96-101.
Adding Dexmedetomidine to Lidocaine for Intravenous Regional Anesthesia, Dilek Memis, MD et al., Anesth Analg 2004;98:835-40.
Mechanism of decongestant activity of x2-adrenoceptor agnosits, Corboz M.R. et al., Pulmonary Pharmacology & Therapeutics 21 (2008) 449-454.
Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline, Haenisch B. et al., Fundam Clin Pharmacol. Dec. 17, 2009.
An Evaluation of Nasal Response Following Different Treatment Regimes of . . . , Morris S. et al., American Journal Rhinology, vol. 11, No. 2, Mar.-Apr. 1997, pp. 109-115(7).
Pharmacological Characterization of Postjunctional a-Adrenoceptors in . . . , Corboz M.R. et al., American Jour of Rhinology, vol. 19, No. 5, Sep.-Oct. 2005, pp. 495-502(8).
Postjuntional a2-adrenoceptors in blood ve3ssels of human nasal mucosa, Ichimura K. et al., Arch Otorhinolaryngol (1988) 245:127-131.
Long-term use of oxy- and xylometazoline nasal sprays induces rebound swelling, tolerance, and nasal hyperreactivity, Graf P., Rhinology 1996, 34(1):9-13.
Alpha 1-receptors at pre-capillary resistance vessels of the human nasal mucosa, Johannssen V et al., Rhinology 1997; 35(4):161-65.
Correspondence A Propos De L'article: <<Traitement Des Glaucomes Par La Brimonidine>>, M. Detry-Morel ET C. Dutrieux< J Fr Ophtalmo1.2001; 24(7): 748-9.
Potent a2A-Adrenoceptor-Mediated Vacoconstriction by Brimonidine in Porcine Ciliary Arteries, Anna Wikberg-Matsson, et al., IOVS, 2001, vol. 42, No. 9, 2049-55.
Medical Management of Chronic Rhinosinusitus—Jean P. Fong, MD, Matthew Ryan, MD (May 2006).
Alpha Synergy Development, Inc.
Claytor Renee
Padmanabhan Sreeni
Wood, Philips, Katz Clark & Mortimer
LandOfFree
Anesthetic compositions and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anesthetic compositions and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anesthetic compositions and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4311025